48 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 Mar 24
Report of Foreign Private Issuer
4:30pm
associated with the ongoing sepsis clinical Phase II trial.
In January 2021, the Company submitted a new grant application to the IIA for reimbursement
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
13 Sep 23
Notice of Annual General Meeting of Shareholders
4:42pm
the Companies Regulations (Rules Regarding Compensation and Expense Reimbursement of External Directors), 2000. For details regarding Mr. Novik’s compensation
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
31 Mar 23
Report of Foreign Private Issuer
4:30pm
to the IIA for reimbursement by the IIA of certain expenses associated with its clinical development program of prevention of cytokine storms and organ
6-K
EX-10.1
ENLV
Enlivex Therapeutics Ltd
30 Dec 22
Report of Foreign Private Issuer
4:02pm
than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii
424B5
mvd 9c82xjsha
30 Dec 22
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.1
91ghp2xb ckp252d
5 Oct 22
Notice of Annual General Meeting of Shareholders
3:00pm
6-K
EX-99.1
cxkc5tp5 254xnaxds
25 May 22
Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant
8:05am
F-3
1m405c2
29 Apr 22
Shelf registration (foreign)
8:14am
6-K
EX-99.1
dfy6jh7gs4a o0g1s
19 Nov 21
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
lui52y 4ebxw
30 Sep 21
Annual and Extraordinary General Meeting of Shareholders
8:01am
6-K
EX-99.1
oswbykmqqh86
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm
6-K
EX-99.1
cizqak10nv t6j4u
28 May 21
Condensed Consolidated Financial Statements
4:33pm
6-K
EX-99.1
95wtfeymdu4pck2byw
18 May 21
Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis
8:03am
6-K
EX-1.1
w7jjha
12 Feb 21
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
5:17pm
424B5
6ejkwnwa6f4a
10 Feb 21
Prospectus supplement for primary offering
5:22pm
424B5
3zqfmcr0mc2khngy
9 Feb 21
Prospectus supplement for primary offering
4:56pm